Amin, N. B., Frederich, R., Tsamandouras, N., Haggag, A. Z., Schuster, T., Zmuda, W., . . . Johnson, M. (2024). Evaluation of an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose‐ranging, phase 2, randomized, placebo‐controlled study. Wiley. https://doi.org/10.1111/dom.16005
Citazione stile Chigago Style (17a edizione)Amin, Neeta B., et al. Evaluation of an Oral Small‐molecule Glucagon‐like Peptide‐1 Receptor Agonist, Lotiglipron, for Type 2 Diabetes and Obesity: A Dose‐ranging, Phase 2, Randomized, Placebo‐controlled Study. Wiley, 2024. https://doi.org/10.1111/dom.16005.
Citatione MLA (9a ed.)Amin, Neeta B., et al. Evaluation of an Oral Small‐molecule Glucagon‐like Peptide‐1 Receptor Agonist, Lotiglipron, for Type 2 Diabetes and Obesity: A Dose‐ranging, Phase 2, Randomized, Placebo‐controlled Study. Wiley, 2024. https://doi.org/10.1111/dom.16005.